What it's for (Indications)
- Travoprost ophthalmic solution is primarily indicated for the reduction of elevated intraocular pressure (IOP) in patients diagnosed with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
- These conditions are characterized by abnormally high pressure within the eye, which, if left untreated, can lead to progressive optic nerve damage and irreversible vision loss, eventually resulting in blindness.
- Travoprost works by effectively lowering this pressure, thereby helping to preserve visual function and prevent disease progression.
- Its efficacy has been well-established in clinical trials, demonstrating a significant and sustained reduction in IOP when used as monotherapy or as adjunctive therapy in combination with other IOP-lowering medications.
- The decision to initiate treatment with travoprost is typically made by an ophthalmologist after a comprehensive ocular examination, assessment of the patient's individual risk factors for glaucoma progression, and consideration of their overall medical history and any concomitant medications.
- The overarching goal of treatment is to reach and maintain a target IOP level that minimizes the long-term risk of glaucomatous optic neuropathy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for travoprost ophthalmic solution is one drop in the conjunctival sac of the affected eye(s) once daily, administered preferably in the evening. Consistent daily administration at the same time is crucial for maintaining optimal intraocular pressure reduction throughout the 24-hour diurnal cycle. Patients should be instructed that if a dose is missed, they should administer the next dose at the regularly scheduled time and should not double the dose to compensate for the missed one. It is imperative to avoid contact between the dropper tip and the eye or any surrounding structures, including fingers, to minimize the risk of bacterial contamination of the solution. If more than one topical ophthalmic medication is being used, the medications should be administered at least five minutes apart to prevent dilution or washout of the preceding dose and to ensure proper absorption of each drug. Patients should also be advised on proper instillation technique, including performing punctal occlusion or gentle eyelid closure after instillation, which can help to reduce systemic absorption and minimize the potential for systemic side effects. |
Safety & Warnings
Common Side Effects
- Travoprost, while generally well-tolerated, can induce various side effects, though their incidence and severity can vary among individuals.
- The most frequently reported ocular adverse effect is ocular hyperemia (redness of the eye), which commonly occurs in a substantial percentage of patients.
- Other prevalent ocular adverse reactions include significant changes in eyelashes, such as increased length, thickness, pigmentation (darkening), and number of eyelashes.
- Patients may also experience alterations in iris pigmentation, particularly in eyes with mixed-color irides (e.
- g.
- , blue-brown, grey-brown, green-brown, or hazel), which may gradually become a darker brown color.
- This change is often permanent.
- Additional common ocular effects include ocular discomfort, dry eye syndrome, pruritus (itching) of the eye, foreign body sensation, and transient blurred vision.
- Less common but reported ocular effects include punctate keratitis, photophobia, conjunctivitis, and macular edema, including cystoid macular edema, especially in aphakic or pseudophakic patients with a compromised posterior lens capsule or known risk factors for macular edema.
- Systemic absorption of travoprost is minimal; consequently, systemic side effects are rare but may include headache, hypertension, and exacerbation of asthma or chronic obstructive pulmonary disease (COPD) in susceptible individuals.
Serious Warnings
- Black Box Warning: Travoprost ophthalmic solution does not carry a formal FDA Black Box Warning. However, it is associated with several serious warnings and precautions that healthcare professionals and patients must be fully aware of. A prominent concern is the potential for gradual changes in eye color, characterized by an increased brown pigmentation of the iris, which can be irreversible. This effect is most frequently observed in patients with mixed-color irides, leading to potential permanent heterochromia, especially if only one eye is treated. Patients should be thoroughly informed about this cosmetic change. Furthermore, travoprost can induce changes in the eyelashes, including increased length, thickness, pigmentation, and number, as well as periorbital and lid changes such as deepening of the eyelid sulcus (periorbital fat atrophy) and darkening of the eyelid skin, which may give an appearance of a sunken eye. These changes may also be irreversible. Patients with a history of intraocular inflammation (e.g., iritis, uveitis) should use travoprost with extreme caution, as it may exacerbate these inflammatory conditions. There is also a recognized risk of cystoid macular edema, particularly in aphakic or pseudophakic patients with a torn posterior lens capsule, or individuals with known risk factors for macular edema. Close monitoring is essential for these high-risk populations. Travoprost should also be used with caution in patients with a history of herpetic keratitis, as prostaglandin analogues have been implicated in the reactivation of herpes simplex virus. Patients wearing contact lenses must remove them before instillation of travoprost and wait at least 15 minutes before reinserting them, due to the absorption of the preservative benzalkonium chloride by soft contact lenses. The long-term safety implications of increased ocular pigmentation and other ocular changes are not yet fully established.
- Several important warnings and precautions are associated with the use of travoprost ophthalmic solution that healthcare providers and patients should be aware of.
- A notable concern is the potential for permanent changes to iris pigmentation, particularly in patients with mixed-color irides (e.
- g.
- , blue-brown, grey-brown, green-brown, or hazel), which may progressively darken to a more uniform brown.
- This effect is believed to be due to an increase in melanin content within the melanocytes in the iris stroma and patients should be fully informed of this irreversible possibility prior to initiating therapy.
- Additionally, increased pigmentation and growth of eyelashes, along with darkening of the eyelid skin, have been reported.
- Travoprost should be used with caution in patients with a history of intraocular inflammation (e.
- g.
- , iritis/uveitis) as it may exacerbate these conditions.
- Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs, predominantly in aphakic, pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
- There is also a risk of bacterial keratitis associated with the use of multiple-dose ophthalmic solutions when the container has been inadvertently contaminated by patients.
- Travoprost has not been adequately evaluated for the treatment of angle-closure, inflammatory, or neovascular glaucoma, and therefore its use in these specific conditions is not recommended.
- Pregnant or lactating women should only use travoprost if the potential benefit justifies the potential risk to the fetus or infant, as animal studies have indicated reproductive toxicity.
How it Works (Mechanism of Action)
Travoprost is a synthetic prostaglandin F2α analog, specifically a highly selective FP prostanoid receptor agonist. Upon topical ocular administration, travoprost is absorbed through the cornea and rapidly hydrolyzed by esterases into its biologically active free acid form. This active metabolite then exerts its pharmacological effect by binding to and activating the FP prostanoid receptors, which are located on cells within the ciliary body and the uveoscleral outflow pathways of the eye. Activation of these specific receptors leads to a significant increase in the outflow of aqueous humor, primarily through the uveoscleral pathway, which represents the non-conventional outflow route. This enhanced uveoscleral outflow directly results in a reduction of intraocular pressure (IOP). Unlike some other classes of glaucoma medications that primarily reduce aqueous humor production, travoprost's predominant action is to facilitate the drainage of aqueous humor from the eye, thereby lowering the pressure within the globe. The reduction in IOP typically commences approximately 2 hours after administration, with the maximum hypotensive effect usually observed around 12 hours post-dosing, and sustained IOP lowering is maintained for at least 24 hours with once-daily evening administration.